The 8 analysts offering 12-month price forecasts for Myriad Genetics Inc have a median target of 26.50, with a high estimate of 34.00 and a low estimate of 14.00. The median estimate represents a -6.13% decrease from the last price of 28.23.
The current consensus among 9 polled investment analysts is to Hold stock in Myriad Genetics Inc. This rating has held steady since February, when it was upgraded from a Sell rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share -$0.16
Reporting Date Nov 09
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.